Production (Stage)
scPharmaceuticals Inc.
SCPH
$3.55
-$0.03-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.98M | 36.33M | 30.28M | 24.05M | 17.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.98M | 36.33M | 30.28M | 24.05M | 17.63M |
| Cost of Revenue | 13.05M | 11.36M | 9.17M | 6.94M | 4.99M |
| Gross Profit | 28.94M | 24.97M | 21.11M | 17.11M | 12.64M |
| SG&A Expenses | 81.61M | 77.65M | 72.52M | 65.33M | 59.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.66M | 101.11M | 93.97M | 84.43M | 77.33M |
| Operating Income | -66.68M | -64.78M | -63.69M | -60.38M | -59.70M |
| Income Before Tax | -90.78M | -85.15M | -80.12M | -60.64M | -57.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.78 | -85.15 | -80.12 | -60.64 | -57.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.78M | -85.15M | -80.12M | -60.64M | -57.71M |
| EBIT | -66.68M | -64.78M | -63.69M | -60.38M | -59.70M |
| EBITDA | -66.66M | -64.76M | -63.67M | -60.36M | -59.67M |
| EPS Basic | -1.91 | -1.91 | -1.91 | -1.56 | -1.49 |
| Normalized Basic EPS | -1.21 | -1.21 | -1.25 | -1.01 | -0.96 |
| EPS Diluted | -1.91 | -1.91 | -1.91 | -1.56 | -1.49 |
| Normalized Diluted EPS | -1.21 | -1.21 | -1.25 | -1.01 | -0.96 |
| Average Basic Shares Outstanding | 192.68M | 177.96M | 163.28M | 155.48M | 155.19M |
| Average Diluted Shares Outstanding | 192.68M | 177.96M | 163.28M | 155.48M | 155.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |